A clinical trial of mupirocin in the eradication of methicillin-resistant Staphylococcus aureus nasal carriage in a digestive disease unit

Journal of Hospital Infection

Volumn 52, Issue 4, 2002, Pages 281-287

  Dupeyron, Catherine ^a   Campillo, B ^a   Bordes, M ^a   Faubert, E ^a   Richardet, J P ^a   Mangeney, N ^a  

^a Hopital Albert Chenevier   (France)

Author keywords

Carriage; Infection; Liver disease; Mupirocin; Staphylococcus aureus

Indexed keywords

METICILLIN; PSEUDOMONIC ACID; ANTIINFECTIVE AGENT;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CARRIER; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; NOSE; PREVALENCE; REINFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; CROSS INFECTION; FECES; FRANCE; GENETICS; HETEROZYGOTE; HOSPITAL SUBDIVISIONS AND COMPONENTS; INFECTION CONTROL; INTRANASAL DRUG ADMINISTRATION; LIVER DISEASE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; NASOPHARYNX; PENICILLIN RESISTANCE; PROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STATISTICS;

ADMINISTRATION, INTRANASAL; ANTI-BACTERIAL AGENTS; CARRIER STATE; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FECES; FEMALE; HOSPITAL UNITS; HUMANS; INCIDENCE; INFECTION CONTROL; LENGTH OF STAY; LIVER DISEASES; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MUPIROCIN; NASOPHARYNX; PARIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 0036886996     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhin.2002.1287     Document Type: Article

References (19)

1. Dupeyron, C, Campillo, B, Mangeney, N, Bordes, M, Richardet, JP, Leluan, G (2001). Carriage of Staphylococcus aureus and of Gram-negative bacilli resistant to third-generation cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections. Infect Control Hosp Epidemiol, 22 427-432.
2. Campillo, B, Dupeyron, C, Richardet, JP (2001). Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect, 127 443-450.
3. British Society of Antimicrobial Agents and Hospital Infection Society. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect 1998; 39: 253-290.
4. Bertino, JS (1997). Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Am J Health-Syst Pharm, 54 2185-2191.
5. Kluytmans, JA, Mouton, JW, Van den Bergh, MF et al. (1996). Reduction of surgical-site infection in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol, 17 780-785.
6. Cimochowski, GE, Harostock, MD, Brown, R, Bernardi, M, Alonzo, N, Coyle, C (2001). Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and non diabetics. Ann Thorac Surg, 71 1572-1579.
7. Kluytmans, JA, Manders, MJ, Van Bommel, E, Verbrugh, H (1996). Elimination of nasal carriage of Staphylococcus aureus in haemodialysis patients. Infect Control Hosp Epidemiol, 17 793-797.
8. Martin, JN, Perdreau-Remington, F, Kartalija, M et al. (1999). A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis, 180 896-899.
9. Comité de l'antibiogramme de la Société Française de Microbiologie. Communiqué 2000-2001. Path Biol 2000; 48: 832-871.
10. Dice, LR (1945). Measures of the amount of ecologic association between species. Ecology, 26 297-302.
11. Chang, FY, Singh, N, Gayowsky, T, Wagener, MM, Marino, IR (1998). Staphylococcus aureus nasal colonization in patients with cirrhosis: prospective assessment of association with infection. Infect Control Hosp Epidemiol, 19 328-332.
12. Chapoutot, C, Pageaux, GP, Perrigault, PF et al. (1999). Staphylococcus aureus nasal carriage in 104 cirrhotic and control patients. A prospective study. J Hepatol, 30 249-253.
13. Casewell, MW, Hill, RL R (1986). Elimination of nasal carriage of Staphylococcus aureus with mupirocin ('pseudomonic acid') - a controlled trial. J Antimicrob Chemother, 17 365-372.
14. Fernandez, C, Gaspar, C, Torrelias, A et al. (1995). A double-blind randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother, 35 399-408.
15. Dobbeling, BN, Breneman, DL, Neu, HC et al. (1993). Elimination of Staphylococcus aureus nasal carriage in healthcare workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis, 17 466-474.
16. Scully, BE, Briones, F, Gu, J et al. (1992). Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med, 152 353-356.
17. Habarth, S, Dharan, S, Hiassine, N, Herrault, P, Auckenthaler, R, Pittet, D (1999). Randomized, placebo- controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 43 1412-1416.
18. Cookson, BD (1998). The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother, 41 11-18.
19. Von Eiff, C, Becker, K, Machka, K, Stammer, H, Peters, G (2001). Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med, 344 11-16.